We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for lumacaftor/ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)
Active ingredients
lumacaftor/ivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Granules and tablets in fixed dose combinations
Indication
For the treatment of Cystic fibrosis
Therapeutic area
Respiratory